Javascript must be enabled to continue!
Data from Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer
View through CrossRef
<div>Abstract<p><b>Purpose:</b> We hypothesize that a gene expression profile characteristic for inflammatory breast cancer (IBC), an aggressive form of breast cancer associated with rapid cancer dissemination and poor survival, might be related to tumor aggressiveness in non-IBC (nIBC).</p><p><b>Experimental Design:</b> RNA from 17 IBC samples and 40 nIBC samples was hybridized onto Affymetrix chips. A gene signature predictive of IBC was identified and applied onto 1,157 nIBC samples with survival data of 881 nIBC samples. Samples were classified as IBC-like or nIBC-like. The IBC signature classification was compared with the classifications according to other prognostically relevant gene signatures and clinicopathologic variables. In addition, relapse-free survival (RFS) was compared by the Kaplan-Meyer method.</p><p><b>Results:</b> Classification according to the IBC signature is significantly (<i>P</i> < 0.05) associated with the cell-of-origin subtypes, the wound healing response, the invasive gene signature, the genomic grade index, the fibroblastic neoplasm signature, and the 70-gene prognostic signature. Significant associations (<i>P</i> < 0.01) were found between the IBC signature and tumor grade, estrogen receptor status, ErbB2 status, and patient age at diagnosis. Patients with an IBC-like phenotype show a significantly shorter RFS interval (<i>P</i> < 0.05). Oncomine analysis identified cell motility as an important concept linked with the IBC signature.</p><p><b>Conclusions:</b> We show that nIBC carcinomas having an IBC-like phenotype have a reduced RFS interval. This suggests that IBC and nIBC show comparable phenotypic traits, for example augmented cell motility, with respect to aggressive tumor cell behavior. This observation lends credit to the use of IBC to study aggressive tumor cell behavior.</p></div>
American Association for Cancer Research (AACR)
Title: Data from Relapse-Free Survival in Breast Cancer Patients Is Associated with a Gene Expression Signature Characteristic for Inflammatory Breast Cancer
Description:
<div>Abstract<p><b>Purpose:</b> We hypothesize that a gene expression profile characteristic for inflammatory breast cancer (IBC), an aggressive form of breast cancer associated with rapid cancer dissemination and poor survival, might be related to tumor aggressiveness in non-IBC (nIBC).
</p><p><b>Experimental Design:</b> RNA from 17 IBC samples and 40 nIBC samples was hybridized onto Affymetrix chips.
A gene signature predictive of IBC was identified and applied onto 1,157 nIBC samples with survival data of 881 nIBC samples.
Samples were classified as IBC-like or nIBC-like.
The IBC signature classification was compared with the classifications according to other prognostically relevant gene signatures and clinicopathologic variables.
In addition, relapse-free survival (RFS) was compared by the Kaplan-Meyer method.
</p><p><b>Results:</b> Classification according to the IBC signature is significantly (<i>P</i> < 0.
05) associated with the cell-of-origin subtypes, the wound healing response, the invasive gene signature, the genomic grade index, the fibroblastic neoplasm signature, and the 70-gene prognostic signature.
Significant associations (<i>P</i> < 0.
01) were found between the IBC signature and tumor grade, estrogen receptor status, ErbB2 status, and patient age at diagnosis.
Patients with an IBC-like phenotype show a significantly shorter RFS interval (<i>P</i> < 0.
05).
Oncomine analysis identified cell motility as an important concept linked with the IBC signature.
</p><p><b>Conclusions:</b> We show that nIBC carcinomas having an IBC-like phenotype have a reduced RFS interval.
This suggests that IBC and nIBC show comparable phenotypic traits, for example augmented cell motility, with respect to aggressive tumor cell behavior.
This observation lends credit to the use of IBC to study aggressive tumor cell behavior.
</p></div>.
Related Results
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Desmoid-Type Fibromatosis of The Breast: A Case Series
Desmoid-Type Fibromatosis of The Breast: A Case Series
Abstract
IntroductionDesmoid-type fibromatosis (DTF), also called aggressive fibromatosis, is a rare, benign, locally aggressive condition. Mammary DTF originates from fibroblasts ...
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Increased life expectancy of heart failure patients in a rural center by a multidisciplinary program
Abstract
Funding Acknowledgements
Type of funding sources: None.
INTRODUCTION Patients with heart failure (HF)...
Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation
Risk Factors and Prognosis Analysis of Patient-Specific HLA Genomic Loss Relapse Following ATG-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation
Abstract
Background
Developments in related haploidentical hematopoietic stem cell transplantation (haplo-HSCT) have made two immune systems with inco...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract
Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Abstract P1-01-15: Clinical relevance of TRIM37 gene expression in breast cancer
Abstract P1-01-15: Clinical relevance of TRIM37 gene expression in breast cancer
Abstract
Background: Tripartite motif-containing protein 37 (TRIM37) is an oncogenic histone H2A ubiquitin ligase that is overexpressed in a subset of breast cancers...

